EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study

Kathleen Connolly, Richard George iD, Sami Omar, Elin Matsson, Magnus Åstrand iD, Magnus Althage, Daniel Pettersen iD, Esha Mohamed, Kelly Fang iD, Joao A C Lima iD, Mirjana Kujacic, Helena Ödesjö iD und 4 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.034067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Kathleen Connolly und 15 weiteren Autor:innen. Beteiligte Einrichtung: Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK. Hauptthemen laut MEDLINE: Heart Failure, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure mortality remains high despite recent progress in pharmacological treatment. AZD3427 is a selective long‐acting analog of relaxin, a vasodilatory hormone with antifibrotic effects. We assessed the safety, pharmacokinetics, and pharmacodynamics of AZD3427 in healthy volunteers and patients with heart failure on standard‐of‐care therapy. Methods and Results In this first‐in‐human, phase 1a/b, randomized, single‐blind, placebo‐controlled study, healthy volunteers were randomized 6:2 to receive a single dose of AZD3427 or placebo by subcutaneous injection in 5 mixed‐ethnicity cohorts (5, 10, 30, 90, or 270 mg) and 1 Japanese‐descent cohort (270 mg), or by intravenous injection in 1 cohort (15 mg). After confirming safety and tolerability in healthy volunteers, 3 cohorts of patients with heart failure and left ventricular ejection fraction ≤40% and 3 cohorts with ejection fraction ≥41% were randomized 6:2 to receive 5 weekly doses of AZD3427 (5, 15, or 45 mg) or placebo by subcutaneous injection. In total, 56 healthy volunteers and 48 patients with heart failure were randomized. AZD3427 was well tolerated at all doses. After subcutaneous administration, AZD3427 was absorbed slowly, and exposure was approximately linear across the dose range. In patients with heart failure, AZD3427 terminal half‐life was 13 to 14 days and there were numerical increases in stroke volume and estimated glomerular filtration rate. No treatment‐emergent antidrug antibodies were detected.

Conclusions

AZD3427 had favorable safety and pharmacokinetic profiles. Hemodynamic changes in patients with heart failure were consistent with the anticipated effects of a relaxin analog. These findings support further development of AZD3427 as a novel long‐term treatment for patients with heart failure. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04630067.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureReceptors, G-Protein-CoupledAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugInjections, IntravenousInjections, SubcutaneousReceptors, PeptideRelaxinSingle-Blind MethodStroke VolumeTreatment OutcomeVentricular Function, Left

Stichwörter der Autor:innen

AZD3427HFmrEFHFpEFHFrEFRXFP1relaxin

Substanzen

Receptors, G-Protein-CoupledReceptors, PeptideRelaxinRXFP1 protein, human

Autor:innen und Institutionen

  • Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK.
  • Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gaithersburg MD.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden.
  • Translational Science and Experimental Medicine, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden.

ORCID-Profile: Richard George, Magnus Åstrand, Daniel Pettersen, Kelly Fang, Joao A C Lima, Helena Ödesjö, Anders Gabrielsen, Marcin Ufnal

Zitieren

APA

Connolly, K., George, R., Omar, S., Matsson, E., Åstrand, M., Althage, M., Pettersen, D., Mohamed, E., Fang, K., Lima, J. A. C., Kujacic, M., Ödesjö, H., Turton, M., Johannesson, P., Gabrielsen, A., & Ufnal, M. (2024). Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.034067

Vancouver

Connolly K, George R, Omar S, Matsson E, Åstrand M, Althage M, et al. Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.034067

BibTeX
@article{Connolly2024,
  author = {Connolly, Kathleen and George, Richard and Omar, Sami and Matsson, Elin and Åstrand, Magnus and Althage, Magnus and Pettersen, Daniel and Mohamed, Esha and Fang, Kelly and Lima, Joao A C and Kujacic, Mirjana and Ödesjö, Helena and Turton, Michelle and Johannesson, Petra and Gabrielsen, Anders and Ufnal, Marcin},
  title = {Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.034067}
}
Kostenlos starten →